From Present to Future: The Shifting Paradigm of Advanced Hepatocellular Carcinoma
- 1 September 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 21 (9) , 1218-1220
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Improved handling of BCLC 2022 update in the management of hepatocellular carcinoma in clinical practiceDigestive and Liver Disease, 2024
- Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinomaJournal of Hepatology, 2023
- The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022ESMO Open, 2023
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Prevention of NAFLD-associated HCC: Role of lifestyle and chemopreventionJournal of Hepatology, 2021
- Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta‐AnalysisHepatology, 2020
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2019
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialThe Lancet Oncology, 2018
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targetsNature Genetics, 2015